Analysis of the FLT3-ITD and NPM1 Mutations in AML Patients With Intermediate Risk Receiving Allogeneic Stem-Cell Transplantation  by Ogasawara, M. et al.
Poster Session II S297was to analyze the impact of CsA levels in the development of grade
2-4 aGVHD in the setting of allo-RIC in the first four weeks after
transplantation.
Patients and Methods: We included 156 consecutive patients [64
(41%) women], median age 52 (17-69) years, who underwent
HLA-identical sibling allo-RIC at a single institution. RIC included
fludarabine 150 mg/m2 plus busulfan 10 mg/kg (for myeloid malig-
nancies n 5 53) or melphalan 70-140 mg/m2 (lymphoid malignan-
cies n 5 103). GVHD prophylaxis was based on CsA plus
methotrexate (MTX) (n 5 121, 78%) or mychopenolate mofetil
(MMF) (n 5 35, 22%). CsA levels were measured at least twice
weekly during the first four weeks (or until discharge) and the dose
was adjusted to maintain blood levels between 200 and 300 ng/ml.
Results:As the use ofMTXvsMMFdid not impact on the incidence
of grades 2-4 aGVHD patients were analyzed together. The median
blood concentrations of CsA at 1st, 2nd, 3rd and 4th weeks after allo-
SCT were 134 (95 CI:10-183), 219 (95 CI: 54-261), 253 (95 CI: 53-
314) and 224 ng/ml (95 CI:30-411) respectively. The number of pa-
tients who were in the optimal range in the 1st, 2nd, 3rd and 4th
weeks after allo-RIC were 34/150 (22%), 92/154 (59%), 86/148
(58%) and 53/123 (56%). Sixty six patients developed grade 2-4
aGVHD for a cumulative incidence of 42% (95% CI 35-51%) at
a median of 38 (range:18-138) days after allo-SCT. In univariate
analysis the variables associated with a higher incidence of 2-4
aGVHDwere: male sex (p5 0.016), female to male donor-recipient
sex combination (p 5 0.05), and median CsA levels in the second (p
5 0.02) and third (p5 0.02) weeks. In multivariate analysis, the only
significant variables associated with higher 2-4 aGVHDwere female
to male donor-recipient sex combination (HR 2; p 5 0.01) and the
median CsA levels in the third week (HR 0.097, p 5 0.039).
Conclusion:The levels of CsA in the immediate post-transplant pe-
riod were suboptimal in almost 50% of patients. Low levels of CsA
were associated with higher incidence of grade 2-4 aGVHD. A
more stringent monitoring and modification of CsA in the early
phase post-Allo-RIC may be helpful to prevent aGVHD.396
ANALYSIS OF THE FLT3-ITD AND NPM1 MUTATIONS IN AML PATIENTS
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PLANTATION
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Background: Chromosomal abnormality is the most important
prognostic factor for AML patients. Recently, prognosis of cytoge-
netically normal AML patients has been reported to be affected by
the presence of fms-like tyrosine kinase 3 gene internal tandem
duplication (FLT3-ITD) and nucleophosmin 1 gene (NPM1)
mutations. In the present study, we analyzed retrospectively the
FLT3-ITD and NPM1 mutations in AML patients with cytogenet-
ically intermediate risk who received allo-SCT and we evaluated the
effect of the mutations on the outcome of allo-SCT.
Patients and Methods: 23 patients (11 males and 12 females) with
a median age of 46 years (range: 27-65) receiving allo-SCT between
2005 and 2009 whose BM samples were available were enrolled in
this study. Allo-SCT consisted of 10 matched siblings, 8 matched
unrelated donors and 5 unrelated cord blood. GVHD prophylaxis
included CsA/ short term MTX (10) or FK/short term MTX (13).
GenomicDNAwas extracted fromPBMCand amplified by PCRus-
ing specific primers. Analysis of FLT3-ITD or NPM1 exon 12 mu-
tations was carried out by either electrophoresis or direct DNA
sequencing.
Results: FLT3-ITD mutation was found in 5 patients (21.7%).
FLT3-ITD mutation occurred only in cytogenetically normal pa-
tients (positivity: 38.5%). On the other hand, NPM1 mutation was
found in 6 patients (26.1%). Acute GVHD above grade II was found
in 4 patients (57.1%)with FLT3-ITDmutationwhile only 3 patients
(20.0%) without FLT3-ITDmutation manifested the complication.
Frequency of acute GVHD above grade II was 33% and 41% in
NPM1 mutation positive and negative patients, respectively. All
the patients with FLT3-ITDmutation manifested relapse of the dis-
ease following allo-SCTwhile relapse occurred in 5 patients (33.3%)without FLT3-ITD mutation. However, there was no marked dif-
ference in relapse rate between patients with or without NPM1 mu-
tation (33% vs. 41%). Median period of overall survival was 0.184
and 1.619 years in FLT3-ITD mutation positive and negative pa-
tients, respectively.
Conclusions: It was demonstrated that the rate of both relapse and
acute GVHD was significantly higher in AML patients with FLT3-
ITD mutation compared to FLT3-ITDmutation negative patients.
NPM1 mutation exerted minimal effect on the incidence of acute
GVHD and relapse of the disease. These results suggested that
allo-SCT patients with cytogenetically intermediate risk can be
stratified to poor prognosis group if FLT3-ITD mutation is
identified.397
PLASMA CYTOKINE PROFILES AT DAY ZERO: MYELOABLATIVE CONDI-
TIONING EXHIBITS A MORE INFLAMMATORY PROFILE THEN REDUCED
INTENSITY CONDITIONING IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Grimley, M.1, Rehman, N.1, Mellor Heinke, S.1, Villanueva, J.1,
Marsh, R.1, Bleesing, J.1, Mehta, P.1, Jordan, M.1, Kim, M.-O.2,
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While myeloablative conditioning (MAC) has been the conven-
tional preparative regimen for allogeneic stem cell transplant, re-
duced intensity conditioning (RIC) has increasingly been used,
especially in non-malignant conditions. MAC has been associated
with a cytokine storm that may contribute to graft versus host disease
(GVHD) while RIC has shown lower tissue damage which may lead
to a lower release of inflammatory cytokines. We hypothesized that
patients receiving MAC would express a more inflammatory subset
of plasma cytokines on Day Zero compared to patients receiving
RIC.
METHODS:Weprospectively collected samples on 52 consecutive
consented patients who underwent allogeneic transplantation at
Cincinnati Children’s Hospital Medical Center between December
2007 and October 2008. Blood samples were collected at Day 0.
Patient Characteristics are in Table 1.
Table 1.
RIC MACNumber of Patients 23 29
Patient Age -median
(range) years
6.7 (0.6-17.9) 8.1 (0.8-19.4)Patient Gender 13 males/10 females 20 males/9 females
Diagnosis 23 non-malignant 12 malignant/17
non-malignantABio-Plex Pro Assay was used tomeasure plasma levels of GM-CSF,
G-CSF, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-
13, IL-17, IFN-g, MCP-1, MIP-1b, TNF-a, IL-18, and MIF.
Plasma concentrations of sTNF-R1 were measured by ELISA. Sol-
uble IL-2 Receptor alpha (sIL2Ra) levels were measured using the
Immulite platform.
RESULTS: Wilcoxon rank sum test was used to compare the
plasma cytokine levels between the RIC and MAC groups. IL-6,
G-CSF, sIL-2Ra, IL-17 and IL-7 plasma levels were found to be dif-
ferent in the two groups (p # 0.05). We additionally analyzed 2
groups within the RIC cohort-10 patients received distal alemtuzu-
mab (between Days -22 and -13 pretransplant) and 12 patients re-
ceived proximal alemtuzumab (between Days -12 and -8
pretransplant). In this analysis, patients who received distal alemtu-
zumab have higher levels of the tested cytokines including IL-1b,
IL-6, IL-8, IFN-g, MIF and TNF-a (p # 0.05).
DISCUSSION:A pro-inflammatory cytokine profile (increased IL-
6, G-CSF and sIL-2Ra) is seen in MAC patients when compared to
RIC patients who have increased levels of differentiation (IL-17) and
growth (IL-7) cytokines. The timing of alemtuzumab prior to trans-
plant affects the cytokine profile on Day 0. Patients receiving distal
alemtuzumab have higher levels of the pro-inflammatory cytokines
